Maxigra

Sildenafil Citrate, the active ingredient in Maxigra, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction and pulmonary arterial hypertension in adult patients. GNH USA supplies Maxigra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sildenafil Citrate acts on the nitric‑oxide/cGMP pathway to improve vascular smooth‑muscle relaxation in specific disease states. - Erectile dysfunction: improves the ability to achieve and maintain an erection sufficient for sexual activity. - Pulmonary arterial hypertension: helps lower pulmonary arterial pressure and enhances exercise capacity.

Sildenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: warmth and redness of the face or upper chest. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy or runny nose. - Visual disturbances: blurred vision or changes in colour perception.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden hearing loss: abrupt decrease or loss of hearing, sometimes accompanied by tinnitus. - Cardiovascular events: rare cases of myocardial infarction or stroke, especially in patients with pre‑existing heart disease.

Before prescribing Maxigra, clinicians should evaluate patient history and potential risk factors. - Cardiovascular assessment: ensure the patient can tolerate sexual activity without undue risk. - Nitrate therapy: avoid concurrent use due to risk of severe hypotension. - Retinal disorders: use with caution in patients with inherited retinal diseases. - Alcohol consumption: limit intake as it may exacerbate hypotensive effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Sildenafil interacts with several drug classes that can modify its safety profile.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause dangerous drops in blood pressure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil plasma concentrations.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., doxazosin): may enhance hypotensive effects. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy of sildenafil. - Other PDE5 inhibitors: concurrent use can increase risk of adverse events.